Background-Helicobacter pylori, the main cause of chronic gastritis, is a class I gastric carcinogen. Chronic gastritis progresses to cancer through atrophy, metaplasia, and dysplasia. Precancerous phenotypic expression is generally associated with acquired genomic instability. Aim-To evaluate the eVect of H pylori infection and its eradication on gastric histology, cell proliferation, DNA status, and oncogene expression. Methods/Subjects-Morphometric and immunohistochemical techniques were used to examine gastric mucosal biopsy specimens from eight controls, 10 patients with H pylori negative chronic gastritis, 53 with H pylori positive chronic gastritis, and 11 with gastric cancer. Results-All patients with chronic gastritis were in a hyperproliferative state related to mucosal inflammation, regardless of H pylori infection. Atrophy was present in three of 10 patients with H pylori negative chronic gastritis and in 26 of 53 with H pylori positive chronic gastritis, associated in 18 with intestinal metaplasia. DNA content was abnormal in only 11 patients with atrophy and H pylori infection; eight of these also had c-Myc expression, associated in six cases with p53 expression. Fifty three patients with H pylori positive chronic gastritis were monitored for 12 months after antibiotic treatment: three dropped out; infection was eradicated in 45, in whom cell proliferation decreased in parallel with the reduction in gastritis activity; atrophy previously detected in 21/45 disappeared in five, regressed from moderate to mild in nine, and remained unchanged in seven; complete metaplasia disappeared in 4/14, and markers of genomic instability disappeared where previously present. In the five patients in whom H pylori persisted, atrophy, metaplasia, dysplasia, and markers of genomic instability remained unchanged. Conclusions-Chronic H pylori infection seems to be responsible for genomic instability in a subset of cases of H pylori positive chronic atrophic gastritis; eradication of H pylori infection can reverse inflammation and the related atrophy, metaplasia, and genomic instability. (Gut 1999;44:789-799) 
Helicobacter pylori, the main cause of chronic gastric disorders, has been defined as a class I gastric carcinogen. 1 However, only a minority of H pylori positive patients with chronic gastritis develop gastric cancer, and the link between H pylori and gastric carcinoma is unclear. 2 Gastric carcinogenesis is a multistep process progressing from chronic gastritis through glandular atrophy, metaplasia, and dysplasia. [3] [4] [5] [6] Atrophic gastritis and intestinal metaplasia may be the long term consequences of H pylori infection, 7 8 but it is debatable whether or not bacterial eradication reverses these lesions. [9] [10] [11] [12] Acquired genomic instability, which is typical of the phenotypic expression of precancerous lesions, generally precedes neoplastic clonal expansion. 13 14 Chronic H pylori infection damages gastric barrier function 15 16 and stimulates gastric cell proliferation, 3 17-22 which leads to mucosal repair, 22 23 but which can also induce cellular DNA damage. 3 17-22 24 25 The most frequent epiphenomenon of DNA alteration is activation of oncogenes and/or mutation of oncosuppressor genes. [26] [27] [28] [29] The role of these genes has been studied in colon carcinogenesis [30] [31] [32] [33] [34] and, to a lesser extent, in gastric carcinogenesis, [34] [35] [36] [37] [38] [39] but their interrelation with H pylori infection has yet to be defined. The aim of our study was to detect the relation between H pylori infection and gastric carcinogenesis evaluated as the appearance of genomic instability and the associated phenotypic expression. To this aim we investigated gastric histology, cell proliferation, DNA content, and bcl-2, p53, and c-Myc expression in patients with chronic gastritis with and without H pylori infection and after H pylori eradication therapy.
Materials and methods

SUBJECTS
The study population consisted of 82 subjects (52 men and 30 women, age range 24-75 years). They were consecutively recruited from 1 January 1995 to 30 June 1995 from a population of 680 subjects referred to our department for dyspepsia according to the following entry criteria: no antisecretory or antibiotic drugs in the previous two months; no anticoagulant drugs in the last week; no severe associated diseases (liver, kidney, cardiovascular, etc). They were subdivided into four groups according to histological features and H pylori status: eight H pylori negative controls aVected by functional dyspepsia with normal gastric histology; 10 patients with H pylori negative chronic gastritis (nCG); 53 patients with H pylori positive chronic gastritis (pCG); and 11 patients with gastric cancer (three early and eight invasive, of which five were intestinal and three diVuse types). The pCG patients were also examined 12 months after eradication therapy (15 days of treatment with omeprazole 20 mg twice a day, clarithromycin 500 mg twice a day, and tinidazole 500 mg twice a day). H pylori status was evaluated by histology and the 13 C-urea breath test as described in the Maastricht consensus report. 40 The presence of CagA protein, a marker of H pylori virulence, 41 was investigated only in 25/53 of pCG patients. Informed consent was obtained from all subjects.
At study entry and at one year after eradication therapy, at least nine gastric biopsy specimens were taken during upper endoscopy in the body, angulus, and antrum of each subject (three from each site). For cancer patients, gastric samples were obtained from the surgical specimen. The specimens were immediately fixed in 10% neutral buVered formalin, embedded in paraYn wax, and routinely processed. Histological, immunohistochemical, morphometric, and DNA ploidy evaluations were performed on all biopsy samples independently by two pathologists. After the independent reviews, each case was evaluated jointly and disagreements were resolved by consensus.
HISTOPATHOLOGICAL DIAGNOSIS
Haematoxylin and eosin stains were used for the histopathological diagnosis; the modified Giemsa stain was used for H pylori identification. Presence of H pylori, degree of inflammatory reaction and glandular atrophy, intestinal metaplasia, and cellular dysplasia were diagnosed and classified according to the updated Sydney system 42 in each biopsy sample. The diagnosis of atrophy, defined as loss of glandular tissue, was based on agreement between the pathologists on at least two samples for each site investigated.
IMMUNOHISTOCHEMISTRY
For each case, 4 µm thick serial sections were cut from paraYn wax blocks, mounted on acidcleaned glass slides, and heated at 55°C for 60 minutes. Slides were dewaxed and rehydrated, Controls  8  35 (10)  37  --------100  -nCG  10  44 (11)  50  30  -++  30  10  ---100  -pCG  53  50 (11)  69  55  +++  +  49  34*  6  21  15  100  15  GC  11  63 (7)  90  ------100  64  27  36 Values are percentages except for age which is mean (SD). nCG, H pylori negative chronic gastritis; pCG, H pylori positive chronic gastritis; GC, gastric cancer; PMN, polymorphonuclear leucocytes; IM, intestinal metaplasia (*total number 18: 16 complete and two incomplete).
then the endogenous peroxidase activity was inhibited by incubation with 3% H 2 O 2 in methanol (20 minutes at room temperature). To reduce non-specific background staining, slides were incubated with 5% goat serum (15 minutes at room temperature). To enhance immunostaining, sections were treated with an antigen retrieval solution (10 mM citric acid monohydrate, pH 6.0, adjusted with 2 M NaOH) and heated three times in a microwave oven at high Immunohistochemical staining reactions for each of the antibodies tested were compared within corresponding areas of the tissue sections from the consecutive slides. The avidin-biotin-peroxidase complex procedure (ABC standard; Vector Laboratories, Burlingame, California, USA) was then performed as described by Hsu et al. 43 Peroxidase activity was detected with diaminobenzidine as substrate. Finally, sections were weakly counterstained with Harris's haematoxylin and coverslipped with a synthetic mounting medium.
Negative controls with normal human serum replacing specific primary antibodies were included in each run. Positive controls were a case of colon adenocarcinoma for p53 protein, a normal lymph node for c-Myc and PCNA, and a case of a low grade follicular lymphoma for bcl-2 protein. Sections were considered positively stained only in cases of unequivocal nuclear staining for p53, c-Myc, and PCNA, and cytoplasmic staining for bcl-2.
The degree of immunopositivity was evaluated semiquantitatively. A total of 300 cells was counted in random fields from representative areas of the lesions, and the immunoreactive cells were roughly assessed and expressed as percentages. The scoring system for all the antibodies tested was: 0-5% (negative); 5-25% (low positivity); 25-50% (moderate positivity); >50% (high positivity).
STAINING AND COUNTING OF NUCLEOLAR ORGANISER REGIONS (AgNORS)
For each case, a 4 µm section was dewaxed in xylene and rehydrated through graded ethanol to deionised distilled water. AgNOR staining was performed as described by Egan et al. 44 The final working solution was obtained by dissolving gelatin in 1% aqueous formic acid at a concentration of 2%, and mixing it with a 60% aqueous silver nitrate solution (1:2, v/v). This silver colloid solution was applied to the sections (60 minutes at room temperature, shielded from daylight). The sections were then washed with deionised distilled water, and counterstained with Mayer's haematoxylin, dehydrated, and mounted with a synthetic medium. The usual controls were performed as described by Crocker and Nar. 
MORPHOMETRIC ANALYSIS
A Leica Quantimet 500C-Image analyser and processing system was used for morphometric analysis. Images were recorded by a JVC TK-1280E videocamera, connected to a Leitz Orthoplan light microscope. A QWIN V01.00 software package elaborated the data. Within the selected fields, a final number of 200 consecutive nuclei of cells from each case were measured with a × 40 lens. Image acquisition and colour detection were performed in "RGB" (an option that allows the selection of red, green, and blue). Artefacts and image overlapping were corrected in Binary Edit. The AgNOR number for each nuclear area, the area of nucleus and each AgNOR, and the total area of AgNOR were calculated automatically, as were AgNOR length, breadth, perimeter, roundness, and the aspect ratio of each nucleus. 46 47 The perimeter was rectified using a correction factor of 1.064. Values are expressed in µm.
DNA PLOIDY
The Feulgen (sulphuric acid-fucsin) technique was used for nuclear DNA staining of a section from each case, deparaYnised in xylene and rehydrated through decreasing concentrations of ethanol. Cellular DNA was quantified using a microprocessor-controlled image analysis system (Leica-Quantimet 500C analyser, a Sony Ccd camera, and a Leitz Orthoplan microscope). Leica-QWIN V0200A software was used to analyse the data. At least 200 cells from each patient were examined in non-consecutive random fields of representative areas of the lesions. The following indexes were determined for each measurement: normal diploid DNA content (2c); 2c deviation index (2cDI), defined as the variance in DNA content of single cells around the normal diploid (2c) DNA peak; 5c exceeding events (5cEE), defined as the percentage of cells with DNA content higher than 5c; DNA malignancy grade (DNA-MG), a logarithmic transformation of the 2cDI value to produce a continuous scale ranging from 0 to 3.0 DNA content. 48 The methodology described here has been fully validated in gastric biopsy samples. 49 
ANTI-CagA SERUM
The H pylori strain CCUG 17874 (CagA+) was denatured in Laemmli buVer 50 at 100°C for five minutes and electrophoresed in a 10% polyacrylamide gel with sodium dodecyl sulphate. Proteins were transferred to nitrocellulose sheets which were saturated with 3% defatted milk in phosphate buVered saline and 0.1% Triton X (Blotto). Strips were cut out, and serum samples were assayed at a dilution of 1:200 in Blotto. After overnight incubation at room temperature, strips were washed with Blotto, and then incubated with anti-human IgG conjugated with peroxidase at room temperature for 90 minutes. After washing, the reaction was visualised by addition of the substrate (H 2 O 2 in a solution of 0.3% 4-chloro-Inaphthol in 0.05 M Tris/HCl buVer, pH 6.8). An anti-CagA antibody raised in rabbit against a recombinant CagA fragment served as a positive control.
STATISTICAL ANALYSIS
We set the power to 0.8, with type I error = 0.05 and control to case ratio 1:1. The aim was to detect a minimal diVerence of 30% between nCG and pCG groups. Data were analysed with the SPSS package for Windows. The categorical variables (H pylori infection, cell infiltration, atrophy, intestinal metaplasia, dysplasia, DNA ploidy, p53, and c-Myc) were analysed using the 2 test or Fisher's exact test. Correlation between these variables was assessed using the Spearman correlation coefficient. The non-parametric Mann-Whitney U test was used to compare the DNA values (2c, 2cDI, 5cEE, and MG), AgNOR area, and PCNA expression in gastric crypt sections of patients with functional dyspepsia and gastritis with and without H pylori infection. The Wilcoxon matched pair test was used to evaluate PCNA expression in gastric crypt sections of patients with gastritis with H pylori infection before and after eradication therapy.
The analysis of the "before" and "after" data in the H pylori positive group given eradication treatment was evaluated with the McNemar test. Table 1 shows the clinical, histological, and immunohistochemical variables of the population studied. Mean age increased in rank order from normal controls to patients with chronic gastritis and to those with gastric cancer; male sex was prevalent in H pylori related disease Figure 1 gives the histological and immunohistochemical features and DNA content in pCG patients. Cell proliferation, assessed by evaluation of PCNA expression (figs 2 and 3) and AgNOR silver staining, number, and morphometric variables, was increased (table 2 and fig 4) with respect to healthy controls in patients with gastritis regardless of H pylori infection, and associated with the inflammation. AgNOR expression was higher (about 3-to 5-fold) in patients with gastric cancer than in the other groups (table 2). PCNA expression was 2-fold higher in the lower basal portion of the gland in pCG patients with intestinal metaplasia compared with pCG patients without intestinal metaplasia (fig 2) . Expression of bcl-2 was preserved in controls and the gastritis groups, regardless of H pylori infection, intestinal metaplasia, and dysplasia ( fig 5A−D) . In gastric cancer, bcl-2 was expressed at very low levels in three early cancers and was not detectable in the remaining eight invasive cancers ( fig 5E) .
Results
Image analysis of DNA content showed aneuploidy in 11/53 pCG patients, confined to biopsy specimens in which atrophy was present, and in all gastric cancer patients ( fig  6) . The DNA values (DNA indexes, 2cDI, 5cEE, and MG) were higher in gastric cancer than in pCG with aneuploidy (table 3) . There were no significant diVerences in DNA values between the remaining groups (nCG with euploidy versus pCG with euploidy; table 3) or with regard to sex and age of patients (data not shown). Aneuploidy was significantly associated with atrophy (11/11) and expression of p53 (6/11) and c-Myc (8/11) oncoproteins ( fig  1 and table 4) .
The expression of c-Myc was low to moderate in 8/53 pCG patients ( fig 7A, B) ; all these 
PMN, polymorphonuclear leucocytes; IM, complete intestinal metaplasia; PCNA, proliferating cell nuclear antigen.
patients also had an abnormal DNA content, and two had glandular dysplasia (fig 1) . A moderate to strong c-Myc positivity was detected in 4/11 gastric cancers (fig 7C) , while c-Myc was undetectable in control subjects and nCG patients.
Finally, p53 was overexpressed in 63% (7/11) of gastric cancers ( fig 8C) and in 15% (8/53) of pCG ( fig 8A, B) ; six of the latter also had abnormal DNA content and gastric metaplasia (fig 1) . No control subject nor nCG patient showed p53 expression.
The frequency of DNA aneuploidy, and p53 and c-Myc expression in relation to histological findings shows that aneuploidy and p53 and c-Myc expression were invariably associated with atrophy and were more pronounced in patients with intestinal metaplasia (fig 1) .
The H pylori CagA status, investigated in 25/53 patients, was positive in 22 and negative in three. Atrophy was present in 54% of the CagA positive patients, intestinal metaplasia in 36%, dysplasia in 4%, DNA aneuploidy in 22%, and c-Myc and p53 expression in 22% and 18% respectively. However, the small number of subjects with CagA negative H pylori prevented statistical evaluation.
One year after antibiotic treatment, the study protocol was repeated in the 53 pCG patients (table 5) . Three patients dropped out. H pylori was eradicated in 90% of patients (45/50), in whom cell proliferation, PCNA expression ( fig  3E) and AgNOR staining ( fig 4C) decreased in parallel with the reduction in inflammatory infiltrate, whereas no significant diVerence was detected in patients with intestinal metaplasia (fig 2) . The intensity of neutrophil infiltration was directly related to the rate of mucosal cell proliferation in the patients who were responsive to H pylori eradication treatment (p<0.02). Atrophy disappeared completely in five patients (all with mild atrophy restricted to the antrum); it regressed from moderate to mild only in the antrum in nine and remained unchanged in seven. Complete metaplasia associated with atrophy disappeared in four of 14 patients. Finally, DNA aneuploidy and p53 and c-Myc expression, previously detected in eight, six, and five of the 45 patients respectively, disappeared.
In the five subjects in whom H pylori infection persisted after eradication therapy, atrophy, metaplasia, dysplasia, and markers of genomic instability remained unchanged.
Discussion
Concurrent or previous H pylori infection is associated with a 2.7-to 12-fold risk of gastric cancer. 2 Carcinogenesis invariably starts with cell hyperproliferation.
2 3 51 52 The relation between H pylori infection, gastric mucosal damage, and the cell proliferation rate is a matter of debate. H pylori urease activity and leucocyte infiltration have a mitogenic eVect, 3 19 53-55 but gastric cell hyperproliferation also occurs independently of H pylori infection. 56 57 In our study, the gastric epithelial proliferative rate, evaluated using PCNA and AgNOR analyses, was increased in gastric cancer and chronic gastritis, regardless of H pylori infection (figs 2-4 and table 2). Therefore mucosal cell hyperproliferation appears to be a constant finding of chronic gastric damage whatever the aetiology, but it is related to inflammatory infiltrates which were prevalently lympho−monocytic in nCG and made up of polymorphonuclear leucocytes in pCG (table  1) . Mucosal hyperproliferation is linked to apoptosis, and there is mounting evidence that H pylori induces apoptosis. 58 59 The bcl-2 proto-oncogen is involved in controlling apoptosis and is related to the initial phase of cancer. 60 61 The expression of the bcl-2 gene was unaltered in our patients with chronic gastritis, regardless of H pylori infection, which supports the idea that H pylori induced apoptosis occurs through a mechanism that is independent of bcl-2 gene expression. 62 bcl-2 gene expression was also preserved in our patients with early gastric cancer, but was undetectable in advanced cancer. This finding contrasts with reports of bcl-2 overexpression in intestinal type gastric cancer. 37 38 It is conceivable that the discrepancy is related to diVerences in populations studied and in the type, staging, and grading of cancer.
A chronic hyperproliferative state may also favour cellular DNA damage. 3 17-22 24 25 We detected a relation between chronic hyperproliferation and cellular DNA damage only in H pylori positive patients with active gastritis. Therefore the cytotoxic eVect of H pylori infection and the related polymorphonuclear leucocyte infiltration may play important roles in the development and progression of mucosal damage. Aberrant DNA is a prognostic indicator for cancer 49 63-65 and seems to be independent of other clinical pathological factors. 66 We detected aneuploidy in all our cancer patients, but we also identified a novel subset of pCG patients with aneuploidy (11/53) (table 3). Aneuploidy was significantly associated with c-Myc and/or p53 expression (fig 1 and table  4) , which are the most widely used markers of genomic instability.
The c-Myc oncogene is implicated in the transformation and progression of mutated cells. [67] [68] [69] In this study it was expressed in 36% of gastric cancer (4/11) and 15% of pCG (8/53) patients. This is a novel finding because the expression of c-Myc has not previously been investigated in chronic gastritis or in relation to H pylori status. c-Myc expression is more frequent in gastric adenocarcinoma than in adenoma and has also been proposed as an aid to diVerentiate between the two conditions. 39 Half of the patients with c-Myc expression and aneuploidy had p53 overexpression, which was also detected in 63% of gastric cancer patients. The mutation of the p53 gene, which we found in 15% of pCG patients, is a common occurrence in colorectal carcinoma where it is related to a poor prognosis and distant metastasis. [30] [31] [32] It has been reported in gastric cancer 34 35 and precancerous gastric lesions 36 but never in relation to H pylori infection.
Interestingly, aneuploidy and c-Myc and p53 expression were not detected in the absence of H pylori contamination or in patients with H pylori infection but without gastric atrophy. Therefore, in our population, the appearance of genomic instability required the presence of both gastric atrophy and chronic H pylori infection (fig 1) . Several studies have shown that patients with preneoplastic and neoplastic gastric epithelial lesions are more likely to be infected by CagA positive strains [70] [71] [72] [73] [74] which possess a genomic insertion called "cag pathogenicity island" which includes genes involved in virulence. 41 Infection by CagA positive H pylori strains increases the risk of developing atrophy and intestinal metaplasia possibly because of the enhanced inflammatory potential shown by these strains. [70] [71] [72] [73] Although investigated only in about 50% of pCG patients, the high prevalence of positivity for CagA (23 of 25 subjects studied) may help to explain the high incidence of atrophy (49%) and intestinal metaplasia (34%) observed in our patients. Furthermore, the enhanced prevalence of DNA aneuploidy and p53 and c-Myc expression in our patients is in agreement with the observation of an increased cancer risk in individuals infected by CagA positive H pylori strains compared with individuals infected by Cag negative H pylori strains 74 and, more in general, in individuals who live in areas with a high rate of CagA positive H pylori strains. 70 Unfortunately, we were not able to verify this hypothesis directly because of the small number of CagA negative patients in this study.
The eVects of H pylori eradication on atrophy and related intestinal metaplasia are controversial and there is no consensus among gastrointestinal pathologists as to the identification and grading of these lesions. In a recent study, no changes in intestinal metaplasia and atrophy were detected after H pylori eradication irrespective of H pylori CagA status. 9 In contrast, we found that H pylori eradication may be followed, one year after treatment, by the disappearance of complete metaplasia and/or reduction of atrophy (table 5) , when both are present in the antrum. Other groups have reported similar results. 11 12 The patchy nature of the lesions and the subjective nature of the interpretation may account for these controversial findings. 75 76 However, according to a recent stringent definition of atrophy, "true irreversible" atrophy is diVerentiated from "apparent" atrophy which is reversed by removal of inflammation. 77 Our finding of disappearance or regression of atrophy, mainly from the antrum, after H pylori eradication suggests that inflammatory infiltration plays a role in this controversial histological finding, even though we cannot rule out the involvement of other factors such as age, sex, diet, genetic makeup of the host, nature of the lesions, biopsy sampling, H pylori strains, and environmental toxic factors. Long term studies and a larger number of stratified patients in relation to age of infection are needed to establish definitely the reversibility of H pylori related lesions and the predictive value of genetic markers for H pylori eradication.
Our data confirm the significant link between such precancerous features as incomplete metaplasia and dysplasia and genomic instability. However, we found genomic instability in four cases not showing these morphological aspects (fig 1) . It is noteworthy that in Barrett's oesophagus, p53 overexpression precedes dysplasia in patients followed for about three years. 78 79 In conclusion, chronic H pylori infection seems to be responsible for genomic instability in a subset of cases of H pylori positive chronic atrophic gastritis and also in the absence of notorious precancerous lesions like metaplasia and dysplasia; eradication of H pylori infection can reverse inflammation and related atrophy, metaplasia, and genomic instability. Finally, we suggest that pCG patients with atrophy should receive eradication treatment for H pylori, while pCG patients with H pylori infection who do not respond to antibiotic treatment should be examined for markers of genomic instability and closely monitored.
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LETTERS TO THE EDITOR
Towards immunotherapy for pancreatic cancer
EDITOR,-McKenzie and Apostolopoulos' recent article on immunotherapy for pancreatic carcinoma (Gut 1999;44:767-769) gave an excellent overview. We agree that the poor prognosis of this disease makes it imperative that new agents and novel therapeutic strategies are investigated. However, although this paper discusses classical immunotherapy (where immune competent cells are stimulated to attack pancreatic cancer cells directly), the induction of antibodies directed against growth factors by immunisation (where the immunogen stimulates the immune system to inhibit the growth of tumour cells indirectly) is not mentioned. We are currently undertaking a phase II clinical trial for inoperable pancreatic cancer using one such immunogen, Gastrimmune, which induces neutralising antibodies against amidated gastrin-17 and its precursor glycine extended gastrin-17 (this immunogen is also undergoing a phase II trial for gastric cancer at the University Department of Surgery, Nottingham, UK).
Gastrin has been shown to be a growth factor in a variety of malignancies including colorectal, gastric, and pancreatic cancers in both in vitro and in vivo studies 1 ; precursor forms such as progastrin and glycine extended gastrin also have a trophic eVect. 2 More recently the autocrine/paracrine pathway, in which tumour cells produce and respond to gastrin, has been shown to be increasingly important. 3 In vitro and in vivo studies have also shown the trophic eVect of gastrin and the inhibitory eVect of both gastrin receptor antagonists and anti-gastrin antibodies, 1 4 5 and further studies have confirmed gastrin expression in human pancreatic cancer cell lines and resection specimens. 4 6 Thus, there is good evidence to suggest that immunisation against gastrin may be beneficial in the prevention of pancreatic cancer.
We have shown that Gastrimmune induced antibodies inhibit the growth of human pancreatic cancer cell lines, 7 and they have previously been shown to inhibit the growth of gastric, colonic, and hepatocellular cancer cell lines in vitro and in vivo. 8 Over 150 patients have now received Gastrimmune in several trials. The side eVect profile has been extremely good and the early eYcacy data in colorectal cancer has been encouraging 9 ; phase III studies are currently being designed for both pancreatic and colorectal cancer.
Pancreatic cancer has an appalling prognosis. New molecular insights provide encouragement that novel therapeutic strategies may improve the outlook. The immune system can be employed directly and indirectly to target pancreatic cancer cells, and we hope the promise of these new strategies is fulfilled in the next decade.
Reply
EDITOR,-Brett and Caplin have highlighted that our paper was biased towards cellular immunotherapy. We specifically excluded reference to antibodies, but welcome the opportunity to mention these in the context of immunotherapy of pancreatic cancer.
In the early 1980s, murine monoclonal antibodies oVered great hope for the diagnosis and cure of cancer, but by the end of the decade, the outlook was pessimistic. Used alone, murine monoclonal antibodies had little eVect, mostly because of the occurrence of HAMA (human anti-mouse response) which curtailed the life of the monoclonal antibody in patients by forming immune complexes; furthermore, the murine Fc pieces of immunoglobulin are particularly poor at marshalling human defence mechanisms to cause inflammation and tumour eradication and thus, these antibodies proved ineVective in the treatment of most types of human cancer. More recently, however, an eVort has been made to "humanise" the antibodies, either by making them as chimeras (essentially murine Fab to bind the antigen, coupled with human Fc), or by retaining only the critical murine amino acids so that the rest of the molecule is human. These techniques are achieved by genetic engineering and sophisticated computer modelling. Principally, such humanised antibodies are less immunogenic than their murine counterpart, but this is not always so, and they should be more active with the human Fc piece, by activating complement and macrophages. However, at present such antibodies and are in phase I/II trials, and with several exceptions (see later), trials have not been particularly rewarding. We are particularly pessimistic about the use of antibodies, be they humanised or not, against solid tumours in humans, as we are experienced in rejecting grafts and with tumour grafts using antibody and complement. 2 For mucin 1, we have not been able to cause rejection of human MUC1+ tumours in mice by using large amounts of monoclonal antibodies and additional complement, under circumstances which lead to rapid destruction of lymphoid cells.
However, total pessimism now seems unwarranted. Firstly, murine antibodies in lymphoma and leukaemia have been found to be particularly useful in the treatment of these diseases. The antibodies need to be "armed", especially with isotopes, and using antibodies to CD19 and CD20 131 I labelled antibodies have been eVective in patients who are resistant to other forms of treatment. 3 Furthermore, it takes a long time for appropriate clinical trials to be completed and more patience is needed before abandoning potentially eVective treatment. A blanket statement that monoclonal antibodies are not eVective in cancer is too broad and this is proved by the use of such antibodies in the treatment of lymphomas; they are particularly sensitive to irradiation and because the patients were immunosuppressed by the disease, they made little HAMA and therefore could be treated successfully.
Antibodies that do not act primarily via their Fc piece by activating complement but have a direct eVect on cell surface molecules are another exception. A well known antibody, Her2/neu, reacts with molecules present in 20-30% of patients with breast cancer. Her2/neu molecules have a growth eVector function and if they can be blocked on the cell surface by the antibody, which inhibits the binding of the ligand (growth factor), the cells die. 4 This has been further illustrated by the use of Gastrimmune against amidated gastrin-17 by Brett and Caplin. Antibodies to other growth factor receptors have also been described, which are proving to be extremely useful in early clinical trials. 4 Thus, selective antibodies against growth factor receptors may be useful in the treatment of diseases like pancreatic cancer. It is possible that the antibodies will be immunogenic and a HAMA or HAHA (human anti-human antibody) response will occur, but this can only be shown by a clinical trial. There may also be problems with antibodies obtaining access to tumours, or tumours not expressing the appropriate molecules as they de-diVerentiate. However, these are problems of any cellular or humoral immune response, and are no longer regarded as being peculiar to antibodies. Thus, it is appropriate to consider special antibodies and growth factors to be part of immunotherapy for pancreatic cancer.
Finally, the colon cancer trial in which patients with Dukes's C disease had improved prognoses after receiving 171A antibody, is of interest, 6 although it has still to be established whether the specific or nonspecific nature of the antibody was responsible for the improvements. Nevertheless, phase III trials are now in progress to assess this. It is easier to treat disease by immunotherapy if treatment starts at an early stage. Unfortunately, early diagnosis of pancreatic cancer remains diYcult-how can a disease with a relatively low frequency be diagnosed in the absence of symptoms? When the symptoms finally appear it may already be too late for immunotherapy. Vitamin D deficiency is a common side eVect of hepatic and gastrointestinal diseases and often results in bone disease; gastroenterologists should, therefore, have some knowledge of the causes, consequences, and treatment of vitamin D related bone disorders. It also has a wide range of actions which are unrelated to its eVects on calcium metabolism; receptors for its active metabolite, 1,25-dihydroxyvitamin D, are found in many places including the stomach, thymus, immune system, gonads, and some cancer cells. The antiproliferative and prodiVerentiation eVects of vitamin D have already been exploited in the development of treatment for psoriasis and other skin disorders and the exciting potential applications of vitamin D in some malignant diseases are discussed towards the end of the book.
Since the pivotal research in the 1960s on the metabolism of vitamin D there has been intense research activity in a number of related areas, including the synthesis and metabolism of vitamin D metabolites and analogues, the molecular biology of the vitamin D receptor, and the mechanisms by which 1,25-dihydroxyvitamin D aVects the renal, intestinal, and skeletal transport of calcium. These aspects are covered in considerable detail and occupy about one half of the book; there is also a detailed chapter on the methodology for assays of vitamin D, although the authors do not discuss the usefulness of these assays in clinical practice. The latter part of the book is devoted to clinical issues-for example, rickets and osteomalacia, osteoporosis, inherited defects of vitamin D metabolism, and the pathophysiology of hypercalcaemia associated with the extrarenal production of 1,25-dihydroxyvitamin D, which occurs in conditions such as sarcoidosis and lymphoproliferative disorders. There is also an interesting chapter on the epidemiology of cancer risk and vitamin D. Disappointingly, at least for the gastroenterologist, there is very little coverage of vitamin D deficiency associated with hepatic and gastrointestinal disorders.
The book is well produced and has many illustrations and diagrams; it provides an excellent and comprehensive account of the substantial advances occurring in this area. Furthermore, the chapters are well referenced, many containing over 100 references. This book is not for the gastroenterologist who wishes to extract information about the diagnosis and management of vitamin D deficiency in clinical practice, but will be highly valued by those with a close interest in following the fascinating progress of this hormone. 
